<DOC>
	<DOC>NCT02927444</DOC>
	<brief_summary>This study will assess the immunogenicity and safety of booster vaccination with NBP606 compared to the existing commercial vaccine, when given concomitantly with routine pediatric vaccinations.</brief_summary>
	<brief_title>Immunogenicity and Safety Study of NBP606 in Healthy Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy infants who completed 3 doses of primary vaccination (NBP606_PCVI_III_2013), available for followups during the study period. The LAR (Legally Authorized Representative) who understand the requirements of the study and voluntarily consent to participate in the study. Administration of other vaccines, except the ones provided in this study, within 1month prior to booster study Known hypersensitivity to any components of the pneumococcal vaccine Any confirmed or suspected immunosuppressive or immunodeficient conditions Coagulation disorder contraindicating IM(intramuscular) vaccination Participation to another study</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>